Author: angelinneed

The August 2026 Editors’ Picks from AACR journals cover the impact of weight loss and omega-3 supplementation on breast cancer risk, early-onset cancer prediction, and more.

The post Editors’ Picks, August 2026: Weight Loss and Breast Cancer Biomarkers, Predicting Early-onset Cancer Cases, and More appeared first on American Association for Cancer Research (AACR).

Ovarian cancer is often diagnosed at an advanced stage, but research is reshaping how scientists understand and treat the disease. From discoveries about its origins to new FDA-approved therapies, learn how scientific advances are creating new possibilities for patients, including the first immunotherapy-based regimen for this cancer type and a first-of-its-kind selective glucocorticoid receptor antagonist.

The post How New Science is Reshaping Ovarian Cancer Treatment and Care appeared first on American Association for Cancer Research (AACR).

Antibody-drug conjugates, or ADCs, have emerged as a significant class of cancer therapies over the past two decades. New research has helped to revolutionize the drug class and deliver next-generation designs and approaches.

The post Smart Chemotherapy Gets Smarter: Advances in Antibody-drug Conjugates appeared first on American Association for Cancer Research (AACR).

A variety of national and local news outlets have highlighted AACR initiatives and experts in recent weeks. Learn about the news stories covering the findings from the AACR Cancer Disparities Progress Report 2026 and AACR’s statement about the White House Office of Management and Budget’s proposal to change how federal grants are awarded and managed.

The post AACR in the News: Cancer Disparities Progress Report and OMB Statement appeared first on American Association for Cancer Research (AACR).

Antibody-drug conjugates, or ADCs, are increasingly common cancer therapies. But what are they? How do they work? And how were they discovered? Learn about the history of ADCs, their functions, the ADCs currently approved by the FDA, and more.

The post What Are Antibody-drug Conjugates? appeared first on American Association for Cancer Research (AACR).

We highlight some of the many innovations showcased at the inaugural AACR Drug Discovery and Development (AACR D3) conference, including investigational KRAS degraders, approaches to drug p53 and MYC, and new AI tools for drug discovery.

The post AACR D3 Offered a Peek Into the Cancer Drug Pipeline, Innovative AI Tools, and More appeared first on American Association for Cancer Research (AACR).

The AACR D3 edition of “From the Bench” highlights cutting-edge approaches from the meeting that could shape the next generation of cancer treatments. We spoke with Andrea Wang-Gillam, MD, PhD, of Jacobio Pharmaceuticals; Kiyean Nam, PhD, of Qurient; Sharanya Nag, PhD, of Memorial Sloan Kettering Cancer Center; and Giuseppina Carbone, MD, about their innovative strategies to inhibit KRAS, enhance antibody-drug conjugate efficacy, and tackle resistance.

The post From the Bench, AACR D3 2026: Emerging Therapeutic Strategies to Inhibit KRAS, Enhance ADCs, and Tackle Resistance appeared first on American Association for Cancer Research (AACR).

With seven CAR T-cell therapies approved by the U.S. Food and Drug Administration, this innovative immunotherapy has revolutionized the treatment of blood cancers in recent years. Here, we provide an overview of how this therapy works and which cancers it’s approved to treat.

The post What Is CAR T-cell Therapy? appeared first on American Association for Cancer Research (AACR).

In July, the editors from AACR’s 10 peer-reviewed journals highlighted research on AI-driven molecular mapping of pancreatic cancer evolution, sex differences in immune responses, the discovery of a new subset of cells that promote brain metastasis, along with several other exciting articles.

The post Editors’ Picks, July 2026: AI-powered Pancreatic Proteomics, Sex-based Immune Differences, and More appeared first on American Association for Cancer Research (AACR).

The summer issue of Cancer Today includes articles about integrating patient-reported outcomes into clinical research and care, advances in preventing and treating graft-versus-host disease, researchers’ efforts to better understand the mechanisms of treatment resistance, advice about divulging a cancer diagnosis when dating, and more.

The post Cancer Today’s Summer 2026 Issue: Using Patient-reported Outcomes to Address Side Effects, Preventing Graft-versus-host Disease, and More appeared first on American Association for Cancer Research (AACR).